News

Stories

See all

2021 Updates: Lilly's Global COVID-19 Response

View Story

Supporting United Way to Meet New Challenges

View Story

Racial Justice Initiative: Confronting Racial Inequities Head On

View Story

How Digital and Remote Health Can Help Next-Generation VBAs

View Story

Meet the Women Behind Our Cancer Research

View Story

Christalyn Rhodes, Ph.D.

Christalyn Rhodes: Living Her Purpose, Our Purpose

View Story


Press Releases

See all

Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes

March 8, 2021

Tags |  Corporate

Biolojic is eligible to receive up to $121 million, consisting of potential milestones and a promissory note, as well as tiered royalties INDIANAPOLIS and TEL AVIV , March 8, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Biolojic Design Ltd.




Lilly to Participate in Barclays Global Healthcare Conference

March 8, 2021

Tags |  Financial

INDIANAPOLIS , March 8, 2021 /PRNewswire/ --  Eli Lilly and Company (NYSE:LLY) will participate in the Barclays Global Healthcare Conference on Tuesday, March 9, 2021 . Patrik Jonsson , senior vice president, president of Lilly USA and chief customer officer, will participate in a virtual fireside




EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union

March 5, 2021

Tags |  Product

CHMP has completed a review of available data for both antibodies for the treatment of confirmed COVID-19 CHMP scientific opinion supports national decision-making within European Union (EU) member states on the use of the antibodies during a public health emergency before a formal marketing




Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The Lancet

March 5, 2021

Tags |  Product

INDIANAPOLIS , March 5, 2021 /PRNewswire/ -- Loxo Oncology at Lilly , a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that The Lancet has published data from the pirtobrutinib (previously referred to as LOXO-305) global Phase 1/2 BRUIN clinical trial in